rozanolixizumab

Ligand id: 9801

Name: rozanolixizumab

No information available.
Summary of Clinical Use
Rozanolixizumab (as research code UCB7665) has progressed to Phase 2 clinical trial in patients with myasthenia gravis (NCT03052751) and primary immune thrombocytopenia (NCT02718716).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02718716 Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia Phase 2 Interventional UCB Pharma
NCT03052751 Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis. Phase 2 Interventional UCB Pharma